First-in-Humans Evaluation of Safety and Dosimetry of (64)Cu-LLP2A for PET Imaging

There remains an unmet need for molecularly targeted imaging agents for multiple myeloma (MM). The integrin very late antigen 4 (VLA4), is differentially expressed in malignant MM cells and in pathogenic inflammatory microenvironmental cells. [(64)Cu]Cu-CB-TE1A1P-LLP2A ((64)Cu-LLP2A) is a VLA4-targe...

Descripción completa

Detalles Bibliográficos
Autores principales: Laforest, Richard, Ghai, Anchal, Fraum, Tyler J., Oyama, Reiko, Frye, Jennifer, Kaemmerer, Helen, Gaehle, Greg, Voller, Tom, Mpoy, Cedric, Rogers, Buck E., Fiala, Mark, Shoghi, Kooresh I., Achilefu, Samuel, Rettig, Michael, Vij, Ravi, DiPersio, John F., Schwarz, Sally, Shokeen, Monica, Dehdashti, Farrokh
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Society of Nuclear Medicine 2023
Materias:
Basic Science Investigation
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9902845/
https://www.ncbi.nlm.nih.gov/pubmed/36008121
http://dx.doi.org/10.2967/jnumed.122.264349

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9902845/
https://www.ncbi.nlm.nih.gov/pubmed/36008121
http://dx.doi.org/10.2967/jnumed.122.264349

Ejemplares similares